[go: up one dir, main page]

AU7005694A - Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism - Google Patents

Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism

Info

Publication number
AU7005694A
AU7005694A AU70056/94A AU7005694A AU7005694A AU 7005694 A AU7005694 A AU 7005694A AU 70056/94 A AU70056/94 A AU 70056/94A AU 7005694 A AU7005694 A AU 7005694A AU 7005694 A AU7005694 A AU 7005694A
Authority
AU
Australia
Prior art keywords
medicament
diseases
manufacture
treatment
oxygenation mechanism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70056/94A
Inventor
Lawrence Bryer & Bizley Hepworth
Alan Norman Howard
David I Thurnham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Howard Foundation
Original Assignee
Howard Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313266A external-priority patent/GB9313266D0/en
Application filed by Howard Foundation filed Critical Howard Foundation
Publication of AU7005694A publication Critical patent/AU7005694A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU70056/94A 1993-06-28 1994-06-28 Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism Abandoned AU7005694A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9313266 1993-06-28
GB939313266A GB9313266D0 (en) 1993-06-28 1993-06-28 Antioxidants for lipoproteins
US21989794A 1994-03-30 1994-03-30
US219897 1994-03-30
PCT/GB1994/001402 WO1995000130A1 (en) 1993-06-28 1994-06-28 Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism

Publications (1)

Publication Number Publication Date
AU7005694A true AU7005694A (en) 1995-01-17

Family

ID=26303133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70056/94A Abandoned AU7005694A (en) 1993-06-28 1994-06-28 Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism

Country Status (4)

Country Link
AU (1) AU7005694A (en)
GB (1) GB2280110B (en)
IL (1) IL110139A0 (en)
WO (1) WO1995000130A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329432B2 (en) 1993-06-28 2001-12-11 The Howard Foundation Mesozeaxanthin formulations for treatment of retinal disorders
JP3501836B2 (en) 1994-02-15 2004-03-02 財団法人産業創造研究所 Antioxidant and antioxidant method using fucoxanthin
GB2289406A (en) * 1994-04-15 1995-11-22 Britannia Health Products Ltd Vitamin, betacarotene and zinc composition for sperm health
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6262109B1 (en) 1995-12-22 2001-07-17 Henkel Corporation Methods of preventing and/or treating high serum levels of cholesterol and/or lipids
AU705467C (en) * 1994-12-22 2002-12-19 Cognis Corporation Pharmaceutical compositions comprising lycopene
NZ309130A (en) * 1995-06-07 2001-06-29 Howard Foundation A pharmaceutical composition containing meso-zeaxanthin optionally with lutein
JP2750281B2 (en) * 1995-06-15 1998-05-13 睦憲 藤原 Hypercholesterolemia treatment
JPH09124470A (en) 1995-10-26 1997-05-13 Suntory Ltd Antistress composition
CN1104235C (en) * 1995-10-31 2003-04-02 应用食品生物技术公司 Pure 3R-3'R stereoisomer of zeaxanthin for the treatment of human macular degeneration
US6140309A (en) * 1996-03-12 2000-10-31 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
IT1283143B1 (en) * 1996-07-12 1998-04-07 Indena Spa METHOD OF EXTRACTION OF THE LYCOPENE AND EXTRACTS THAT CONTAIN IT
EP0966960A1 (en) * 1996-11-27 1999-12-29 Dainippon Ink And Chemicals, Inc. Agent for inhibiting carcinogenesis or tumor metastasis
JP2001511153A (en) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン Compositions and methods for prevention and treatment of vascular degenerative diseases
SE522246C2 (en) 1997-02-27 2004-01-27 Astacarotene Ab Oral preparation for prophylactic and therapeutic treatment of Helicobacter Sp. infection
AU752468B2 (en) * 1997-04-04 2002-09-19 Phyllis E. Bowen Lutein esters having high bioavailability
SE512531C2 (en) 1997-09-04 2000-03-27 Astacarotene Ab Use of at least one type of xanthophyll for the manufacture of a medicament for the prophylactic and / or therapeutic improvement of mammalian muscle function and / or treatment of mammalian muscle disorders or disorders
SE524337C2 (en) 1998-10-16 2004-07-27 Astacarotene Ab Use of at least one type of xanthophyll for the manufacture of a medicament for the prophylactic and / or therapeutic treatment of indigestion
NL1010351C2 (en) * 1998-10-19 2001-01-08 Werklust & Beheer B V Carotenoid esters for use in the prevention and treatment of eye diseases.
IL129442A0 (en) * 1999-04-14 2000-02-29 Lycored Natural Prod Ind Ltd Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood
AU776732B2 (en) * 1999-10-04 2004-09-23 John Carter Pharmaceutical compositions containing copper, salicylic acid and vitamines C
HU227182B1 (en) * 2000-03-06 2010-09-28 Andras Javor Lecitin-ascorbic acid combination
WO2002010770A2 (en) * 2000-07-31 2002-02-07 Neuronautics, Inc. Improved methods for identifying reagents which inhibit tau polymerization
GB2374008B (en) * 2001-04-04 2005-03-16 John Carter Pharmaceutical compositions comprising copper and zinc
GB0119052D0 (en) * 2001-08-03 2001-09-26 Mars Uk Ltd Foodstuff
GB0202900D0 (en) 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
NZ564486A (en) 2002-02-25 2009-03-31 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
KR101017668B1 (en) * 2003-08-25 2011-02-25 디퓨젼 파마슈티컬즈 엘엘씨 Bipolar Trans Carotenoid Salts and Their Uses
US7351424B2 (en) 2004-07-22 2008-04-01 Bio Lut S.A. De C.V. Enhanced purity trans-lutein-ester compositions and methods of making same
CN104840455A (en) 2005-02-24 2015-08-19 扩散药品有限公司 Trans carotenoids, their synthesis, formulation and uses
JP5099812B2 (en) * 2006-04-07 2012-12-19 株式会社カネカ Blood sugar level rise inhibitor
WO2007116980A1 (en) * 2006-04-07 2007-10-18 National University Corporation Hokkaido University Suppressor of increase in blood glucose level
US20070293568A1 (en) 2006-06-16 2007-12-20 Yamaha Hatsudoki Kabushiki Kaisha Neurocyte Protective Agent
JP5223083B2 (en) * 2006-06-21 2013-06-26 国立大学法人京都大学 Angiogenesis inhibitor
US8293804B2 (en) 2007-04-13 2012-10-23 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease
KR20100083820A (en) 2007-10-31 2010-07-22 디퓨젼 파마슈티컬즈 엘엘씨 A new class of therapeutics that enhance small molecule diffusion
CN108464976A (en) 2009-06-22 2018-08-31 扩散药品有限公司 Diffusion promotes compound and its independent or application together with Thrombolytic Drugs
TWI492744B (en) 2009-12-04 2015-07-21 Abbott Lab Methods of modulating inflammation in preterm infants using carotenoids
CA2801292C (en) 2010-06-02 2019-01-22 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2012040938A1 (en) * 2010-09-30 2012-04-05 北京绿色金可生物技术股份有限公司 Use of fucoxanthin in the preparation of product having neuroprotective effect associated with neurodegenerative disorder and improving memory
WO2014155189A1 (en) 2013-03-28 2014-10-02 Omniactive Health Technologies Ltd. Neuroprotective effect of carotenoids in brain
CN115089569A (en) 2016-03-24 2022-09-23 扩散药品有限公司 Use of bipolar trans carotenoids in conjunction with chemotherapy and radiation therapy for the treatment of cancer
GB201618350D0 (en) * 2016-10-31 2016-12-14 Ip Science Ltd Methods and compositions comprising carotenoids

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH552388A (en) * 1970-07-10 1974-08-15 Hoffmann La Roche LIGHT PROTECTION AGENTS.
DE2923032A1 (en) * 1979-06-07 1980-12-11 Waldemar Hankin Pharmaceutical compsn. contg. heron egg yolk - for restoring balance between iron and gold in the blood
FR2558372B1 (en) * 1984-01-25 1987-08-07 Oreal DRUG COMPOSITION FOR THE TREATMENT OF ACNE
IL88961A (en) * 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
DE3812567A1 (en) * 1988-04-15 1989-10-26 Basf Ag METHOD FOR PRODUCING PHARMACEUTICAL MIXTURES
JP2619491B2 (en) * 1988-08-11 1997-06-11 サントリー株式会社 Astaxanthin-containing composition
DE69019035T2 (en) * 1989-02-28 1995-08-31 Nisshin Flour Milling Co Stabilized fat-soluble vitamin compositions.
IL90794A (en) * 1989-06-29 1995-03-15 Shapira Niva Nutritional sun-exposure supporting composition
DK546289D0 (en) * 1989-11-02 1989-11-02 Danochemo As carotenoid
WO1992005780A1 (en) * 1990-10-01 1992-04-16 Brigham And Women's Hospital Beta-carotene and vitamin e therapy for inhibition of major vascular events
DE4141351A1 (en) * 1991-12-14 1993-06-17 Basf Ag STABLE POWDERFUL VITAMIN AND / OR CAROTINOIDE PREPARATES AND PROCESS FOR THEIR PREPARATION

Also Published As

Publication number Publication date
WO1995000130A1 (en) 1995-01-05
GB9412938D0 (en) 1994-08-17
IL110139A0 (en) 1994-10-07
GB2280110A (en) 1995-01-25
GB2280110B (en) 1997-11-12

Similar Documents

Publication Publication Date Title
AU7005694A (en) Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism
AU5384096A (en) Use of vitamin D2 or vitamin D4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
AU7867994A (en) Hemofiltration of mediator-related diseases
AU4048295A (en) Peptide medicaments for the treatment of disease
AU3560495A (en) Medicament inhaler
AU2845492A (en) Dipyridamole for the treatment of proliferative diseases
AU6916694A (en) Novel treatments for allergic diseases
AU8910891A (en) Treatment of lung diseases
EP0765663A3 (en) Use of dienogest for the manufacture of a medicament for the treatment of the skin by topical application
AU4477893A (en) Use of C1-inactivator for the production of a pharmaceutical for the prophylaxis and therapy of certain diseases
AU9173191A (en) Medicaments for the treatment of papillomavirus diseases
AU1116895A (en) Use of theophylline for the manufacture of a medicament for the treatment of asthma
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU2787495A (en) Use of copolymer-1 for the manufacture of a medicament for the treatment of optic neuritis
AU3684395A (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
AU7982098A (en) Use of beta2-adrenoceptor agonists for the manufacture of a medicament for the treatment of scoliosis
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
AU3574793A (en) Remedy for airway diseases
AU5658094A (en) Use of potassium channel activators for the manufacture of a medicament for the treatment of pain
AU8185491A (en) Treatment of disease
AU4081393A (en) Medicaments for the treatment of anxiety
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
AU665052B2 (en) The use of a compound for the manufacture of a medicament for the treatment of HIV infection
AU7103594A (en) Treatment of neonatal hyperbilirubin with metalloporphyrin